Bioject announces the appointment of a distributor for China
TIGARD, Ore., May 12, 2014
TIGARD, Ore., May 12, 2014 /PRNewswire/ --Bioject Medical Technologies Inc.
(OTC Pink: BJCT), a leading developer of needle-free injection systems
continues to expand global access to the company's technology. Bioject has
signed an agreement with Caligor RX, Inc. to use its China distribution
partners to sell its commercial devices in the region.
"We are looking forward to working with Bioject to bring this important
technology to the People's Republic of China," commented Joseph Safdie,
Caligor RX Vice President and Corporate Counsel, "We anticipate a successful
collaboration that will provide a significant benefit to public health in
"Caligor RX has an extensive network of business resources in China that will
provide an exceptional base for marketing and sales of our products," stated
Mark Logomasini, Bioject's President and CEO. "This agreement represents a
significant step forward in the company's goal of establishing itself as the
standard in needle-free technology around the world, particularly in areas
where there is an acute appreciation of the public health consequences of
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a
developer and manufacturer of needle-free injection therapy systems (NFITS).
NFITS works by forcing medication at high speed through a tiny orifice held
against the skin. This creates a fine stream of high-pressure fluid
penetrating the skin and depositing medication in the tissue beneath. Bioject
is focused on developing mutually beneficial agreements with leading
pharmaceutical, biotechnology, and veterinary companies, as well as research,
global health and government organizations.
Caligor Rx is an international pharmaceutical supply company engaged in
efficient, cost-effective sourcing and supply of comparator drugs for clinical
trials worldwide. Caligor Rx is licensed to ship all drugs, including
Schedules II-V, anywhere in the world. Headquartered in Secaucus with
facilities in Europe, the company's operations include state-of-the art
warehousing and distribution, complete with monitored cold chain and ambient
storage capabilities. Through our relationships with leading manufacturers and
suppliers, we specialize in helping our customers put the right comparator
sourcing strategy in place for their needs.
Readers and potential investors are cautioned that an investment in the
Bioject's securities involve an EXTREMELY high degree of risk. Such risks
include, without limitation, the risk that the distribution agreement will not
be successful due to the time required in obtaining government clearances and
the risk that the Company may be unable to comply with the extensive
government regulations applicable to the international business.
Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market.
Investors can find Real-Time quotes and market information for the Company on
For more information about Bioject and CaligorRX visit www.bioject.com and
SOURCE Bioject Medical Technologies Inc.
Contact: Mark Logomasini, President and CEO, Bioject Medical Technologies
Inc., 503-692-8001, or Joseph Safdie, VP and Corporate Counsel, Caligor RX,
Press spacebar to pause and continue. Press esc to stop.